Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer

Author's Avatar
Oct 06, 2020
Article's Main Image

Durable Anticancer Activity Observed in Patients Whose Cancer Had Progressed Despite Prior Treatment With Chemotherapy and/or Immunotherapy

Safety and Tolerability Similar to Previously Reported Phase 1 Results in Patients with Non-Small Cell Lung Cancer

PR Newswire